India is widely known as the “Pharmacy of the World,” supplying affordable generic medicines to over 150 countries. However, despite this global dominance in generics, India remains significantly behind in original drug discovery and high-value innovation.
At a time when the global pharmaceutical industry is rapidly shifting toward AI-driven drug development, biologics, and precision medicine, India faces a critical challenge—whether it can transition from a low-margin generic manufacturer to an innovation-driven pharmaceutical powerhouse.
Without timely reforms, the current regulatory delays and structural gaps risk pushing India out of the next wave of global pharmaceutical leadership.
Major Developments Shaping India’s Pharmaceutical Sector
1. Upstream Self-Reliance
India is aggressively reducing its dependency on imports for critical Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) to secure supply chains. This marks a shift from a vulnerable formulator-only model to vertically integrated manufacturing.
- Under the PLI scheme for bulk drugs, investments reached ₹4,814 crore (against ₹4,329 crore committed) by December 2025.
- Created 56,800 Metric Tonnes Per Annum (MTPA) capacity for APIs/KSMs.
2. Breakthrough in Indigenous Antimicrobials
India has developed Nafithromycin, the first indigenously conceptualized and clinically validated antibiotic.
- Addresses the growing Antimicrobial Resistance (AMR) crisis
- Demonstrates India’s capability in first-in-class drug innovation
3. Transition to Pharma 4.0
The sector is moving toward AI-driven drug discovery and Digital Biology.
- Use of Digital Twins for clinical trial simulations
- AI-powered pharmacovigilance systems
- Clinical trials market projected to reach USD 2,954.1 million by 2033
→ Helps compress traditional drug development timelines significantly.
4. Mega Bulk Drug & Medical Device Parks
The government is developing cluster-based infrastructure to reduce costs.
- 3 Bulk Drug Parks approved (FY 2022–23) in Andhra Pradesh, Gujarat, Himachal Pradesh
- Common Infrastructure Facilities (CIF) reduce capital burden on MSMEs
5. Quality Harmonization: Revised Schedule M
In 2024, Schedule M under the Drugs and Cosmetics Rules was revised, expanding GMP (Good Manufacturing Practices) requirements to cover premises, plant, equipment, and quality processes, thereby aligning Indian standards more closely with global benchmarks.
India currently has:
- Largest number of USFDA-compliant plants outside the US
- Over 2,000 WHO-GMP approved facilities
- Exports to 150+ countries
Quality compliance is now a market access requirement.
6. High-Value Diversification
Indian pharma is moving beyond generics into high-value segments like New Biological Entities (NBEs) and biosimilars to tap upcoming global patent expiries.
There is PRIP scheme (Promotion of Research and Innovation in Pharma) for advanced therapies such as CAR-T and mRNA.
7. Transition to High-End Medical Devices
India is shifting from being a net importer of medical technology to a hub for high-end diagnostic and surgical equipment through dedicated industrial parks and incentive schemes.
- PLI scheme for medical devices (₹3,420 crore)
- By Sept 2025: 22 projects operationalized
8. Biopharma Ecosystem Push
- Launch of “Biopharma SHAKTI” initiative (Union Budget 2026–27)
- Expansion of National Institutes of Pharmaceutical Education and Research (NIPERs)
Focus on biologics and next-gen therapies.
9. Green Pharma and ESG Transition
Industry is moving toward:
- Green chemistry and flow chemistry
- Renewable energy adoption
→ Essential for compliance with global Environmental, Social, and Governance (ESG) standards (EU, US markets).
What are the Key Issues Associated with India’s Pharma Sector?
1. Quality Perception Crisis – The “Spurious Drug” Stigma
Recurrent global alerts regarding contaminated Indian-made syrups and eye drops have severely dented the “Brand India” reputation, highlighting inconsistent adherence to Good Manufacturing Practices (GMP).
Failure to harmonize quality across MSMEs leads to a fragmented regulatory landscape where substandard products jeopardize international trust and patient safety.
For instance, inspections conducted by CDSCO in collaboration with state regulators, covering 905 units, revealed widespread non-compliance, with 694 regulatory actions taken (December 2025)—highlighting persistent gaps in GMP adherence.
2. The Innovation Deficit – R&D Underinvestment
India remains a “Generic Superpower” but an “Innovation Laggard”, with most firms focusing on incremental improvements rather than high-risk, high-reward New Chemical Entities (NCEs).
High capital costs and long gestation periods deter private investment, keeping India dependent on Western intellectual property for specialty drugs.
In terms of R&D intensity, global firms outperform Indian firms by a factor of 3.0.
While the PRIP (Promotion of Research and Innovation in Pharma) scheme offers support, India’s share in global pharma innovation remains limited.
3. Persistent Import Vulnerability – The API Chokepoint
Despite PLI schemes, India continues to depend heavily on China for fermentation-based APIs and high-end Key Starting Materials (KSMs), creating a strategic supply chain vulnerability.
Volatile geopolitical conditions and price fluctuations expose Indian pharma to external shocks.
For instance, India still imports 65–70% of its total API requirements (by value) from China.
4. Regulatory Overlap and Pricing Friction
The industry faces a complex regulatory structure involving CDSCO, National Pharmaceutical Pricing Authority (NPPA), and State Licensing Authorities, leading to compliance burden and delays.
Expansion of the National List of Essential Medicines (NLEM) creates a “margin squeeze”, as rising input costs cannot be passed to consumers.
The average price reduction under NLEM (2022) was about 17%, discouraging MSMEs from upgrading to advanced technologies.
5. Talent Mismatch and Skill Gaps
There is a growing gap between traditional pharmacy education and Industry 4.0 requirements, including bioinformatics, clinical data science, and complex biologics.
India produces a relatively low number of PhDs in specialized fields like computational chemistry, limiting its ability to scale innovation in Cell and Gene Therapy (CGT) and mRNA segments.
6. The “Silent” Climate Risk – ESG Compliance
The sector faces a growing decarbonization challenge, as global markets—especially the EU—mandate strict Environmental, Social and Governance (ESG) standards.
Pharmaceutical cleanrooms consume up to 15 times more energy than standard buildings, with over 50% electricity used in HVAC systems, making green transition difficult for MSMEs.
7. The Digital Divide – Data and Cyber Risks
Despite the push toward Pharma 4.0, many firms operate with data silos, where manufacturing, quality, and R&D systems are not integrated.
This leads to documentation errors and regulatory warnings. Additionally, increasing digitalization has created a cybersecurity risk, exposing critical systems to ransomware attacks.
8. The “Biosimilar Paradox”
Transitioning into biosimilars is constrained by patent thickets and high development costs.
- Biosimilars: >$100 million cost, 5–9 years
- Generics: $1–2 million, ~2 years
They also require specialized cold-chain logistics and higher regulatory trust, making it difficult for smaller firms to compete.
What Measures Should India Adopt to Strengthen and Advance its Pharmaceutical Sector?
Regulatory Harmonization – Toward “Single-Window” Governance
India needs to consolidate fragmented state-level licensing into a unified framework under a “National Pharmaceutical Regulatory Authority.” This “One Nation, One Regulator” approach can eliminate overlaps and reduce compliance fatigue.
Standardizing Good Manufacturing Practices (GMP) across MSMEs and aligning audits with WHO-PICS standards will ensure global quality consistency.
Digitizing the entire “Lab-to-Market” lifecycle through an integrated portal can significantly reduce approval timelines for innovative drugs.
R&D Renaissance – Risk Sharing and Innovation Push
To move beyond generics, India must support high-risk research through Innovation Bonds and Viability Gap Funding (VGF) for New Chemical Entities (NCEs).
Creating Centres of Excellence with strong industry–academia–clinician linkages can bridge the “Valley of Death” in drug discovery.
A Patent Box Tax Regime with incentives for domestic intellectual property can accelerate the shift toward New Biological Entities (NBEs).
Supply Chain Fortification – Beyond PLI
India must strengthen upstream self-reliance through Circular Bio-Manufacturing and green chemistry to reduce dependence on external suppliers.
Developing plug-and-play infrastructure in Bulk Drug Parks with shared facilities (effluent treatment, solvent recovery) will support MSMEs.
Incentivizing backward integration into Key Starting Materials (KSMs) will reduce vulnerability to global supply disruptions.
Accelerating Pharma 4.0 and AI Integration
Adoption of Digital Twin technology and AI-driven predictive modelling can optimize production and shorten clinical trial timelines.
Implementing blockchain-enabled traceability across the supply chain can curb counterfeit drugs and restore “Brand India” trust.
Using Real-World Evidence (RWE) in regulatory approvals can enable faster access to critical therapies.
Human Capital Upskilling
India must upgrade its pharmacy education to include computational biology, genomics, and advanced bioprocessing.
Establishing industrial finishing schools in collaboration with global firms will create an industry-ready workforce.
Promoting global talent corridors and reverse brain drain through research fellowships can strengthen leadership in CGT and mRNA sectors.
Strategic Market Diversification
India should focus on orphan drugs and neglected tropical diseases (NTDs) to gain early-mover advantage in underserved markets.
Providing fast-track market exclusivity for indigenous drugs targeting domestic health challenges (e.g., AMR) can create a sustainable innovation-to-revenue cycle.
Government-backed purchase guarantees can support high-risk pharmaceutical innovation.
ESG-Led Global Integration
Adopting carbon-neutral manufacturing is essential to maintain access to regulated markets like the EU and US.
Transitioning to renewable energy-based facilities and flow chemistry can reduce environmental impact.
Positioning India as a “sustainably sourced pharma hub” can help capture a green premium in global markets.
Conclusion
India stands at a critical inflection point—between its legacy as a global generic leader and its aspiration to become an innovation-driven pharmaceutical powerhouse. Bridging regulatory gaps, strengthening R&D, and adopting AI-led “Pharma 4.0” will shape its future trajectory.
A strategic shift toward quality, sustainability, and high-value biologics is essential to remain globally competitive. With timely reforms, India can move from being the “Pharmacy of the World” to a leader in next-generation drug innovation.